Breast cancer
We form a long-term antitumor defense, reducing the risks of relapses and metastasis.
About the disease
Breast cancer usually responds well to first-line treatment - surgery, chemotherapy, hormone and targeted therapy. Holding on to that result is harder. After treatment, single tumor cells can remain in the body and, years later, grow into a recurrence or metastases. Immunotherapy targets exactly this problem.
We train the patient's immune cells to recognize proteins specific to breast tumor cells. After the course, immune surveillance keeps finding and destroying residual tumor cells that are not yet visible on scans.
The method is especially relevant after radical surgery, when the goal is to reduce the risk of the disease returning. It also helps with triple-negative breast cancer, where the tumor has no targets for hormone therapy. In metastatic disease, immunotherapy is used as part of comprehensive treatment.
Unlike chemotherapy, which hits all rapidly dividing cells, immunotherapy relies on the body's own cells. It is therefore tolerated more gently, without severe toxicity, and can be combined with surgery, drug therapy, and radiation.
Immunotherapy complements standard treatment rather than replacing it. The physician builds the regimen after assessing the tumor subtype by its receptors, the stage, prior treatment, and medical records. There is no single protocol; each case gets its own program.
Recurrence prevention
After surgery, immune surveillance keeps searching for residual tumor cells.
Helps with triple-negative cancer
Works where the tumor has no targets for hormone therapy.
Gentler than chemotherapy
The body's own cells work, without severe toxicity.
Combines with standard treatment
Complements surgery, chemo, hormone, and radiation therapy.
Tailored to the tumor subtype
The program is built around receptor status and stage.
Extracorporeal immunotherapy
We move the immune 'training' process outside the body (ex vivo) — to an environment where we can create the conditions for training immunocompetent cells without creating any risk to your body.
Procedure
We draw your venous blood (up to 90 ml).
Activation (18 hours)
In the laboratory, using our proprietary technology (patents in Russia, the US, and the EU), we incubate the cells with immunomodulatory drugs and xenogeneic antigens. The cells receive a precise target.
Strike
We return the trained cells via subcutaneous injections. A powerful, multi-component immune response is developed.
Consolidation
The maintenance course forms long-term immunological memory, protecting against relapses for years.
Frequently asked questions
How does immunotherapy help with breast cancer?
The method builds long-term antitumor immunity. It helps destroy residual tumor cells after surgery and reduces the risk of the disease returning.
Does the method help with triple-negative breast cancer?
Yes, this is one of the main indications. In the triple-negative subtype the tumor has no receptors for hormone therapy, so the immune approach is especially valuable alongside chemotherapy and surgery.
Can immunotherapy be combined with surgery and chemotherapy?
Yes. Immunotherapy complements surgical and drug treatment, strengthens the result of surgery, and does not add a heavy toxic burden on the body.
Does immunotherapy reduce the risk of recurrence and metastasis?
That is exactly its aim. Trained immune cells keep monitoring the body after the main treatment and remove single tumor cells, which are usually what a recurrence grows from.
How hard is the treatment to tolerate?
The effect is gentle: the body's own cells do the work. The method is therefore much easier to tolerate than aggressive chemotherapy and lets you keep your usual quality of life.
How much does treatment cost and can I come from another region?
Oncology programs start from RUB 285,000; the physician gives the exact figure after a consultation and review of your records. The clinic is near Moscow (Khimki, Skhodnya) and accepts patients from other regions; the first consultation can be held remotely.
Other directions
Melanoma
Activation of your own cells to destroy metastases. Proven efficacy even at advanced stages.
Kidney cancer
Specific immune response against renal cell carcinoma without severe toxic burden.
Ovarian cancer
Adoptive therapy opening new treatment possibilities even when chemotherapy standards are exhausted.
Discuss your situation
Leave your contact details. Our medical coordinator will contact you shortly to answer any questions.